JETRO has announced the selection of 10 overseas regenerative medicine startups for the Japan Entry Acceleration Program (JEAP), an initiative supporting foreign life science companies seeking to enter and scale in the Japanese market.

The program targets startups developing advanced regenerative medicine and cell therapy technologies, providing support such as expert mentoring, regulatory guidance, and business matching with Japanese pharmaceutical institutions. JEAP aims to accelerate commercialization while strengthening international collaboration within Japan’s life sciences ecosystem.

Following a competitive screening process, selected startups originate from the United States, the United Kingdom, Sweden, and Finland. They cover a range of therapeutic areas, including immunotherapies for solid tumors, mesenchymal stem cell–based treatments for autoimmune diseases, next-generation CAR-T platforms, and stem cell technologies targeting ophthalmic and neurological disorders.

‍